Loading…
Employees: 29
Size Faeth Therapeutics (FTH) is a United States Health Care company (Biotechnology) with a market value of $570M, the 2603rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $22.05 on 6 Nov 2026.
Performance Over six months the shares fell 5.8%, against -16.6% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 17 in its peer set.
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$106,000 | -$139,000 | -$551,000 | -$571,000 | -$1.81M |
| EBITDA | -$74.3M | -$22.1M | -$31.1M | -$36.5M | -$47.3M |
| Net income | -$211M | -$21.1M | -$30.2M | -$34.1M | -$48.6M |
| Free cash flow | -$43.3M | -$20.5M | -$24.8M | -$32.2M | -$39.3M |
| Capital expenditure | $9,000 | $16,000 | $146,000 | $180,000 | $321,000 |
| Total debt | $145,000 | $1.51M | $3.85M | $6.21M | $8.03M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FTH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.9% | -14.1% | 11th highest of 21 |
| 6-month return | -5.8% | -16.6% | 5th highest of 17 |
| Distance from 52-week high | -47.7% | -44.9% | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | 25.7× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | 6.5× | n/a | n/a |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | 7.0× | 31.6% | +7.0% |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | 4.0× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 2.2× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 5.4× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 8.0× | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 48.0× | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | 13.7× | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | 3.8× | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |